Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 9/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.40 |
| ▸ | MGLL | Q99685 | 6/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | ASPH | Q12797 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30490333 | 0.85 | P2RX3 (0.45) | ABHD6LOXL2MGLLP2RX3P2RX2 | |
| SCHEMBL23849991 | 0.81 | LIPG (0.49) | ABHD6MGLLLIPGSCN9AHSD11B1 | |
| Trifluoroacetic Acid SCHEMBL23850604 | 0.80 | P2RX3 (0.36) | ABHD6LOXL2MGLLLIPGHCRTR1 | |
| SCHEMBL23850598 | 0.78 | LOXL2 (0.40) | ABHD6LOXL2MGLLFFAR1HSD11B1 | |
| SCHEMBL25409272 | 0.77 | LOXL2 (0.41) | ABHD6LOXL2MGLLFFAR1 | |
| SCHEMBL25301218 | 0.76 | LOXL2 (0.47) | ABHD6LOXL2MGLL | |
| SCHEMBL25252074 | 0.75 | LOXL2 (0.43) | ABHD6LOXL2MGLLHCRTR1HCRTR2 | |
| SCHEMBL21813871 | 0.71 | UGT8 (0.49) | — | |
| SCHEMBL21825422 | 0.71 | LIPE (0.44) | LIPGFFAR1 | |
| SCHEMBL21814142 | 0.71 | LOXL2 (0.39) | ABHD6LOXL2MGLLP2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3883936-B1 | NEW HETEROCYCLIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2023-07-12 | — | — | EP | disclosed |
| US-20210387999-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2021-12-16 | — | — | US | disclosed |
| EP-3883936-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2021-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210387999-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP4B1, CYP4X1 | ABHD6 2881/4885LOXL2 329/4885MGLL 1712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.